Ampio Pharmaceuticals, Inc. (AMPE)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -8.63 Million USD | -1.95% |
| 2022 | -8.46 Million USD | 32.18% |
| 2021 | -12.48 Million USD | 24.32% |
| 2020 | -16.49 Million USD | -89.98% |
| 2019 | -8.68 Million USD | -125.55% |
| 2018 | 33.98 Million USD | 165.49% |
| 2017 | -51.89 Million USD | -170.78% |
| 2016 | -19.16 Million USD | 40.13% |
| 2015 | -32.01 Million USD | 16.04% |
| 2014 | -38.12 Million USD | -58.8% |
| 2013 | -24 Million USD | -107.09% |
| 2012 | -11.59 Million USD | 36.85% |
| 2011 | -18.35 Million USD | -127.97% |
| 2010 | -8.05 Million USD | -30813.96% |
| 2009 | -26.05 Thousand USD | 18.29% |
| 2008 | -31.88 Thousand USD | 0.36% |
| 2007 | -31.99 Thousand USD | -3086.75% |
| 2006 | -1004.00 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 FY | -8.63 Million USD | -1.95% |
| 2023 Q2 | -1.37 Million USD | 62.69% |
| 2023 Q1 | -3.67 Million USD | -74.58% |
| 2023 Q3 | -1.22 Million USD | 10.36% |
| 2023 Q4 | -2.05 Million USD | -67.13% |
| 2022 Q3 | -6.41 Million USD | -205.0% |
| 2022 Q1 | -5.63 Million USD | 9.4% |
| 2022 FY | -8.46 Million USD | 32.18% |
| 2022 Q4 | -2.1 Million USD | 67.17% |
| 2022 Q2 | -2.1 Million USD | 62.72% |
| 2021 Q4 | -6.22 Million USD | -71.55% |
| 2021 Q3 | -3.62 Million USD | -2.02% |
| 2021 Q1 | -3.66 Million USD | 20.58% |
| 2021 Q2 | -3.55 Million USD | 3.03% |
| 2021 FY | -12.48 Million USD | 24.32% |
| 2020 Q2 | -2.73 Million USD | 47.27% |
| 2020 FY | -16.49 Million USD | -89.98% |
| 2020 Q1 | -5.17 Million USD | -407.79% |
| 2020 Q3 | -3.36 Million USD | -23.32% |
| 2020 Q4 | -4.61 Million USD | -37.08% |
| 2019 Q3 | -7.21 Million USD | -1815.73% |
| 2019 FY | -8.68 Million USD | -125.55% |
| 2019 Q4 | -1.01 Million USD | 85.87% |
| 2019 Q2 | 420.76 Thousand USD | 107.24% |
| 2019 Q1 | -5.81 Million USD | -481.02% |
| 2018 Q3 | 5.8 Million USD | 25.56% |
| 2018 Q4 | 1.52 Million USD | -73.71% |
| 2018 FY | 33.98 Million USD | 165.49% |
| 2018 Q1 | 22.03 Million USD | 151.1% |
| 2018 Q2 | 4.62 Million USD | -79.04% |
| 2017 Q2 | -2.6 Million USD | -36.99% |
| 2017 FY | -51.89 Million USD | -170.78% |
| 2017 Q4 | -43.12 Million USD | -914.04% |
| 2017 Q3 | -4.25 Million USD | -63.04% |
| 2017 Q1 | -1.9 Million USD | 43.23% |
| 2016 FY | -19.16 Million USD | 40.13% |
| 2016 Q4 | -3.35 Million USD | 15.97% |
| 2016 Q2 | -5.05 Million USD | 25.32% |
| 2016 Q1 | -6.76 Million USD | 32.39% |
| 2016 Q3 | -3.99 Million USD | 20.98% |
| 2015 Q4 | -10 Million USD | -35.84% |
| 2015 Q2 | -7.35 Million USD | -0.99% |
| 2015 Q1 | -7.28 Million USD | 26.52% |
| 2015 Q3 | -7.36 Million USD | -0.14% |
| 2015 FY | -32.01 Million USD | 16.04% |
| 2014 Q2 | -8.69 Million USD | 15.14% |
| 2014 Q4 | -9.91 Million USD | -6.81% |
| 2014 Q3 | -9.28 Million USD | -6.77% |
| 2014 FY | -38.12 Million USD | -58.8% |
| 2014 Q1 | -10.24 Million USD | -39.53% |
| 2013 FY | -24 Million USD | -107.09% |
| 2013 Q2 | -6.41 Million USD | -53.58% |
| 2013 Q3 | -6.07 Million USD | 5.38% |
| 2013 Q4 | -7.34 Million USD | -20.88% |
| 2013 Q1 | -4.17 Million USD | -13.63% |
| 2012 Q4 | -3.67 Million USD | -42.31% |
| 2012 FY | -11.59 Million USD | 36.85% |
| 2012 Q3 | -2.58 Million USD | -3.53% |
| 2012 Q2 | -2.49 Million USD | 11.99% |
| 2012 Q1 | -2.83 Million USD | 32.25% |
| 2011 Q4 | -4.18 Million USD | -62.52% |
| 2011 Q1 | -8.77 Million USD | -194.43% |
| 2011 FY | -18.35 Million USD | -127.97% |
| 2011 Q3 | -2.57 Million USD | 8.61% |
| 2011 Q2 | -2.81 Million USD | 67.9% |
| 2010 Q1 | -1.48 Million USD | -25843.86% |
| 2010 Q2 | -1.14 Million USD | 22.62% |
| 2010 Q3 | -2.44 Million USD | -113.11% |
| 2010 Q4 | -2.98 Million USD | -22.04% |
| 2010 FY | -8.05 Million USD | -30813.96% |
| 2009 FY | -26.05 Thousand USD | 18.29% |
| 2009 Q1 | -10.63 Thousand USD | -110.74% |
| 2009 Q4 | -5711.00 USD | -13.2% |
| 2009 Q3 | -5045.00 USD | -8.31% |
| 2009 Q2 | -4658.00 USD | 56.21% |
| 2008 Q2 | -3318.00 USD | 79.75% |
| 2008 Q3 | -7132.00 USD | -114.95% |
| 2008 Q4 | -5048.00 USD | 29.22% |
| 2008 FY | -31.88 Thousand USD | 0.36% |
| 2008 Q1 | -16.38 Thousand USD | -86.57% |
| 2007 Q4 | -8781.00 USD | -15.13% |
| 2007 Q1 | -300.00 USD | -19.52% |
| 2007 Q2 | -15.28 Thousand USD | -4995.67% |
| 2007 FY | -31.99 Thousand USD | -3086.75% |
| 2007 Q3 | -7627.00 USD | 50.11% |
| 2006 FY | -1004.00 USD | 0.0% |
| 2006 Q4 | -251.00 USD | 0.0% |
| 2006 Q3 | -251.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -28.96 Million USD | 70.195% |
| Armata Pharmaceuticals, Inc. | -69.04 Million USD | 87.498% |
| Actinium Pharmaceuticals, Inc. | -48.81 Million USD | 82.318% |
| Azitra, Inc. | -11.28 Million USD | 23.501% |
| Can-Fite BioPharma Ltd. | -7.63 Million USD | -13.073% |
| Chromocell Therapeutics Corporation | -7.38 Million USD | -16.952% |
| Calidi Biotherapeutics, Inc. | -29.21 Million USD | 70.455% |
| CEL-SCI Corporation | -32.36 Million USD | 73.33% |
| iBio, Inc. | -24.9 Million USD | 65.343% |
| Lineage Cell Therapeutics, Inc. | -21.48 Million USD | 59.825% |
| MAIA Biotechnology, Inc. | -19.77 Million USD | 56.344% |
| Matinas BioPharma Holdings, Inc. | -22.94 Million USD | 62.375% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | 43.125% |
| NovaBay Pharmaceuticals, Inc. | -9.64 Million USD | 10.456% |
| NanoViricides, Inc. | -8.29 Million USD | -4.073% |
| Oragenics, Inc. | -20.65 Million USD | 58.21% |
| BiomX Inc. | -26.16 Million USD | 67.014% |
| BiomX Inc. | -26.16 Million USD | 67.014% |
| Protalix BioTherapeutics, Inc. | 8.31 Million USD | 203.85% |
| Palatin Technologies, Inc. | -29.73 Million USD | 70.971% |
| Scorpius Holdings, Inc. | -45.21 Million USD | 80.91% |